Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease

doi:10.4254/wjh.v16.i2.211

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1376)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

945

Figures (1-4)

Tables (1-3)

Sum=1145

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

150

Sum=201

Feb 27, 2024 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Feb 27, 2024; 16(2): 211-228
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.211

Full Size Figure Download Figure

Figure 3 The cumulative incidence of study outcomes in the acute phase vs post-acute phase of infection. A: Hepatocellular carcinoma; B: All-cause mortality; C: Adverse hepatic outcomes; D: Palliative care. HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.

Citation: Mak LY, Chung MSH, Li X, Lai FTT, Wan EYF, Chui CSL, Cheng FWT, Chan EWY, Cheung CL, Au ICH, Xiong X, Seto WK, Yuen MF, Wong CKH, Wong ICK. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease. World J Hepatol 2024; 16(2): 211-228
URL: https://www.wjgnet.com/1948-5182/full/v16/i2/211.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i2.211